There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on December 15, PDL BioPharma Inc's Vice President, CFO, Peter S. Garcia, invested $52,444.50 into 15,000 shares of PDLI, for a cost per share of $3.50. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

Click here to find out which 9 other dividend bargains you can buy cheaper than insiders »

In trading on Monday, bargain hunters could buy shares of PDL BioPharma Inc ( PDLI - Get Report) and achieve a cost basis 11.6% cheaper than Garcia, with shares changing hands as low as $3.09 per share. PDL BioPharma Inc shares are currently trading up about 1.3% on the day. The chart below shows the one year performance of PDLI shares, versus its 200 day moving average:

PDL BioPharma Inc Chart

Looking at the chart above, PDLI's low point in its 52 week range is $2.58 per share, with $7.43 as the 52 week high point — that compares with a last trade of $3.16. By comparison, below is a table showing the prices at which PDLI insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
12/07/2015 Steffen Pietzke Controller and CAO 20,590 $3.64 $74,931.13
12/15/2015 Peter S. Garcia Vice President, CFO 15,000 $3.50 $52,444.50

The current annualized dividend paid by PDL BioPharma Inc is $0.20/share, currently paid in quarterly installments, and its most recent dividend has an upcoming ex-date of 03/02/2016. Below is a long-term dividend history chart for PDLI, which can be of good help in judging whether the most recent dividend with approx. 6.4% annualized yield is likely to continue.


According to the ETF Finder at ETF Channel, PDLI makes up 1.12% of the SuperDividend U.S. ETF ( DIV) which is trading up by about 0.8% on the day Monday.